These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 8986680

  • 1. Somatostatin treatment reduces the exaggerated response of adrenocorticotropin hormone and cortisol to corticotropin-releasing hormone in polycystic ovary syndrome.
    Lanzone A, Fulghesu AM, Guido M, Cucinelli F, Caruso A, Mancuso S.
    Fertil Steril; 1997 Jan; 67(1):34-9. PubMed ID: 8986680
    [Abstract] [Full Text] [Related]

  • 2. Corticotropin-releasing hormone induces an exaggerated response of adrenocorticotropic hormone and cortisol in polycystic ovary syndrome.
    Lanzone A, Petraglia F, Fulghesu AM, Ciampelli M, Caruso A, Mancuso S.
    Fertil Steril; 1995 Jun; 63(6):1195-9. PubMed ID: 7750588
    [Abstract] [Full Text] [Related]

  • 3. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis.
    Azziz R, Black V, Hines GA, Fox LM, Boots LR.
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2317-23. PubMed ID: 9661602
    [Abstract] [Full Text] [Related]

  • 4. The effects of alcoholism on the hypothalamic-pituitary-adrenal axis: interaction with endogenous opioid peptides.
    Inder WJ, Joyce PR, Ellis MJ, Evans MJ, Livesey JH, Donald RA.
    Clin Endocrinol (Oxf); 1995 Sep; 43(3):283-90. PubMed ID: 7586596
    [Abstract] [Full Text] [Related]

  • 5. Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion.
    Ambrosi B, Bochicchio D, Fadin C, Colombo P, Faglia G.
    J Endocrinol Invest; 1990 Mar; 13(3):257-61. PubMed ID: 1973178
    [Abstract] [Full Text] [Related]

  • 6. Evidence of a disturbance of the hypothalamic-pituitary-adrenal axis in polycystic ovary syndrome: effect of naloxone.
    Lanzone A, Guido M, Ciampelli M, Fulghesu AM, Pavone V, Proto C, Caruso A, Mancuso S.
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):73-7. PubMed ID: 8796141
    [Abstract] [Full Text] [Related]

  • 7. Classification of polycystic ovary syndrome into three types according to response to human corticotropin-releasing hormone.
    Kondoh Y, Uemura T, Ishikawa M, Yokoi N, Hirahara F.
    Fertil Steril; 1999 Jul; 72(1):15-20. PubMed ID: 10428142
    [Abstract] [Full Text] [Related]

  • 8. Altered morning and nighttime pulsatile corticotropin and cortisol release in polycystic ovary syndrome.
    Invitti C, De Martin M, Delitala G, Veldhuis JD, Cavagnini F.
    Metabolism; 1998 Feb; 47(2):143-8. PubMed ID: 9472960
    [Abstract] [Full Text] [Related]

  • 9. Lack of effect of desmopressin on ACTH and cortisol responses to ovine corticotropin-releasing hormone in anorexia nervosa.
    Foppiani L, Sessarego P, Valenti S, Falivene MR, Cuttica CM, Giusti Disem M.
    Eur J Clin Invest; 1996 Oct; 26(10):879-83. PubMed ID: 8911861
    [Abstract] [Full Text] [Related]

  • 10. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC, Rizos D, Valsamakis G, Deligeoroglou E, Grigoriou O, Chrousos GP, Creatsas G, Mastorakos G.
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [Abstract] [Full Text] [Related]

  • 11. Influence of body mass on the hypothalamic-pituitary-adrenal-axis response to naloxone in patients with polycystic ovary syndrome.
    Guido M, Ciampelli M, Fulghesu AM, Pavone V, Barini A, de Marinis L, Cento R, Caruso A, Lanzone A.
    Fertil Steril; 1999 Mar; 71(3):462-7. PubMed ID: 10065783
    [Abstract] [Full Text] [Related]

  • 12. The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone.
    Schroeder S, Wichers M, Klingmüller D, Höfer M, Lehmann LE, von Spiegel T, Hering R, Putensen C, Hoeft A, Stüber F.
    Crit Care Med; 2001 Feb; 29(2):310-6. PubMed ID: 11246311
    [Abstract] [Full Text] [Related]

  • 13. Human corticotropin-releasing hormone test in patients with hypothalamo-pituitary-adrenocortical disorders.
    Fukata J, Shimizu N, Imura H, Hibi I, Tanaka K, Tanaka T, Nakagawa S, Takebe K, Kimura K, Yoshinaga K.
    Endocr J; 1993 Oct; 40(5):597-606. PubMed ID: 7951526
    [Abstract] [Full Text] [Related]

  • 14. Desmopressin and low-dose ACTH test in rheumatoid arthritis.
    Foppiani L, Cutolo M, Sessarego P, Sulli A, Prete C, Seriolo B, Giusti M.
    Eur J Endocrinol; 1998 Mar; 138(3):294-301. PubMed ID: 9539304
    [Abstract] [Full Text] [Related]

  • 15. Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy.
    Cleare AJ, Miell J, Heap E, Sookdeo S, Young L, Malhi GS, O'Keane V.
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3545-54. PubMed ID: 11502777
    [Abstract] [Full Text] [Related]

  • 16. Gonadotropin-releasing hormone agonist in premenopausal women does not alter hypothalamic-pituitary-adrenal axis response to corticotropin-releasing hormone.
    Gavin KM, Shea KL, Gibbons E, Wolfe P, Schwartz RS, Wierman ME, Kohrt WM.
    Am J Physiol Endocrinol Metab; 2018 Aug 01; 315(2):E316-E325. PubMed ID: 29631362
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of hypothalamo-pituitary-adrenocortical function in children by human corticotropin-releasing hormone (MCI-028) test.
    Tanaka T, Hibi I, Shimizu N, Imura H, Tanaka K, Fukata J, Fujieda K, Ichimura T, Kuribayashi T, Ito K.
    Endocr J; 1993 Oct 01; 40(5):581-9. PubMed ID: 7951524
    [Abstract] [Full Text] [Related]

  • 18. Combined dexamethasone suppression-corticotrophin-releasing hormone stimulation test in medication-free major depression and healthy volunteers.
    Sher L, Oquendo MA, Burke AK, Cooper TB, Mann JJ.
    J Affect Disord; 2013 Dec 01; 151(3):1108-12. PubMed ID: 23866302
    [Abstract] [Full Text] [Related]

  • 19. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response.
    Nikisch G, Mathé AA, Czernik A, Thiele J, Bohner J, Eap CB, Agren H, Baumann P.
    Psychopharmacology (Berl); 2005 Oct 01; 181(4):751-60. PubMed ID: 15988572
    [Abstract] [Full Text] [Related]

  • 20. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome.
    Romualdi D, Giuliani M, Draisci G, Costantini B, Cristello F, Lanzone A, Guido M.
    Fertil Steril; 2007 Jul 01; 88(1):131-8. PubMed ID: 17336978
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.